The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
| Autor: | Simon Rule, Paul Smith, Peter W.M. Johnson, Simon Bolam, George Follows, Joanne Gambell, Peter Hillmen, Andrew Jack, Stephen Johnson, Amy A Kirkwood, Anton Kruger, Christopher Pocock, John F. Seymour, Milena Toncheva, Jan Walewski, David Linch |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Haematologica, Vol 101, Iss 2 (2016) |
| Druh dokumentu: | article |
| ISSN: | 0390-6078 1592-8721 |
| DOI: | 10.3324/haematol.2015.128710 |
| Popis: | Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease, there is no established gold standard therapy. Rituximab has been used widely to good effect in B-cell malignancies but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of six years, rituximab improved the median progression-free survival from 14.9 to 29.8 months (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|